Before serving as CEO and Managing Director, Paul Perreault's most recent role was President of CSL Behring. He was responsible for overseeing operations in more than 25 countries, including major manufacturing sites in the United States, Switzerland, Germany and Australia, and an extensive network of plasma collection centers throughout North America and Germany.
Prior to becoming President of CSL Behring, Paul was Executive Vice President, Worldwide Commercial Operations with responsibility for all commercial and business development activities globally. He joined CSL Behring in 2004 when CSL Limited acquired Aventis Behring.
Paul held several executive positions at Aventis Behring including Vice President and General Manager of Plasma Operations at Aventis Bio-Services, and Vice President and General Manager for Aventis Behring Hospital Products in North America and Puerto Rico. Prior to this, he spent 16 years in key senior roles at Wyeth-Ayerst Laboratories, now owned by Pfizer. Paul has more than 30 years of experience in the global healthcare industry.
Paul holds a bachelor’s degree in psychology from the University of Central Florida and completed advanced business management training at the Kellogg and Wharton schools of business.
In early 2018, Paul was named Australian Financial Review’s 2017 CEO of the Year.